These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 1773550)

  • 21. Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients.
    Kampf D; Borner K; Pustelnik A
    Eur J Clin Pharmacol; 1992; 42(1):95-9. PubMed ID: 1541323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.
    Hoyer J; Schulte KL; Lenz T
    Clin Pharmacokinet; 1993 Mar; 24(3):230-54. PubMed ID: 8462229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure.
    Asari A; Iles-Smith H; Chen YC; Naderer OJ; Johnson MA; Yuen GJ; Otto V; Dunn JA; Gokal R
    Br J Clin Pharmacol; 2007 Dec; 64(6):738-44. PubMed ID: 17662093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of ofloxacin. An overview.
    Flor S
    Am J Med; 1989 Dec; 87(6C):24S-30S. PubMed ID: 2603892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacokinetics and protein-binding of fusidic acid in patients with severe renal failure requiring either haemodialysis or continuous ambulatory peritoneal dialysis.
    Brown NM; Reeves DS; McMullin CM
    J Antimicrob Chemother; 1997 Jun; 39(6):803-9. PubMed ID: 9222051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and pharmacokinetics of single dose intravenous ofloxacin in healthy volunteers.
    Guay D; Tack K; Flor S
    Int J Clin Pharmacol Res; 1991; 11(5):203-9. PubMed ID: 1814841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis using 99mTc-solid meal.
    Hubalewska A; Stompór T; Płaczkiewicz E; Staszczak A; Huszno B; Sułowicz W; Szybiński Z
    Nucl Med Rev Cent East Eur; 2004; 7(1):27-30. PubMed ID: 15318307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
    Stojimirović B; Grujić-Adanja G
    Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Procainamide pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Raehl CL; Moorthy AV; Beirne GJ
    Nephron; 1986; 44(3):191-4. PubMed ID: 2431330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
    MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
    Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of intravenous and intraperitoneal ceftazidime in chronic ambulatory peritoneal dialysis.
    Demotes-Mainard F; Vinçon G; Ragnaud JM; Morlat P; Bannwarth B; Dangoumau J
    J Clin Pharmacol; 1993 May; 33(5):475-9. PubMed ID: 8331207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diuretic effect and pharmacokinetic data observed at different stages of chronic renal failure with 240 mg of muzolimine.
    Baumelou A; Singlas E; Ritter W; Merdjan H; Martre H; Brouard R; Chickh-Touami C; Patte R
    Z Kardiol; 1985; 74 Suppl 2():88-91. PubMed ID: 4002810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacokinetics of ofloxacin administered orally in elderly subjects with bronchial or urinary tract infections].
    Bardin C; Clavier M; Darchis JP; Chauvin M; Veyssier P; Farinotti R
    Therapie; 1992; 47(1):35-9. PubMed ID: 1523592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disposition kinetics of cefamandole during continuous ambulatory peritoneal dialysis.
    Bliss M; Mayersohn M; Arnold T; Logan J; Michael UF; Jones W
    Antimicrob Agents Chemother; 1986 Apr; 29(4):649-53. PubMed ID: 3707113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clearance of iopamidol, a non-ionic contrast medium, by CAPD in patients with end-stage renal failure.
    Donnelly PK; Burwell N; McBurney A; Ward JW; Walls J; Watkin EM
    Br J Radiol; 1992 Dec; 65(780):1108-13. PubMed ID: 1286420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis.
    Sica DA; Comstock T; Harford A; Eshelman F
    Eur J Clin Pharmacol; 1987; 32(6):587-91. PubMed ID: 3653228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis.
    Browning MJ; Holt HA; White LO; Chapman ST; Banks RA; Reeves DS; Yates RA
    J Antimicrob Chemother; 1986 Jul; 18(1):103-6. PubMed ID: 3463556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy.
    Kaptein EM; Levenson H; Siegel ME; Gadallah M; Akmal M
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3058-64. PubMed ID: 10999786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.